Literature DB >> 35147235

Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population-based analysis in response to CVS 2022 formulary changes.

Ghadeer K Dawwas1,2,3, Adam Cuker4,5, Jean Marie Connors6, Geoffrey D Barnes7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35147235      PMCID： PMC8986609          DOI： 10.1002/ajh.26494

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

2.  Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.

Authors:  Wayne A Ray; Cecilia P Chung; C Michael Stein; Walter Smalley; Eli Zimmerman; William D Dupont; Adriana M Hung; James R Daugherty; Alyson Dickson; Katherine T Murray
Journal:  JAMA       Date:  2021-12-21       Impact factor: 157.335

3.  Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.

Authors:  Ghadeer K Dawwas; Charles E Leonard; James D Lewis; Adam Cuker
Journal:  Ann Intern Med       Date:  2021-12-07       Impact factor: 25.391

4.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang
Journal:  Blood Adv       Date:  2020-10-13
  4 in total
  1 in total

Review 1.  HIF in Gastric Cancer: Regulation and Therapeutic Target.

Authors:  Mengqing Li; Guan Li; Xiaodong Yang; Weihua Yin; Guoqing Lv; Shubin Wang
Journal:  Molecules       Date:  2022-07-31       Impact factor: 4.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.